There is ample evidence that underscores ST6Gal1-mediated expression and α2,6 sialylation of β1-integrin in mammary cancer (Hedlund et al., 2008; Lu et al., 2014), HCC (Han et al., 2018), gliomas (Kroes and Moskal, 2016), ovarian cancer (Christie et al., 2008; Choi et al., 2018), CRC (Seales et al., 2005b) and even in adipogenesis (Kaburagi et al., 2017). Here, ST6GAL1 is linked to ovarian carcinoma.